← Leaderboards
Mathias Lichterfeld
Massachusetts General Hospital
$34,368,889
Attributed
$62,220,990
Total exposure
21
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.8M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$62,220,990 · 21
By mechanism
U01$32,344,246 · 4
R01$19,479,614 · 7
R61$3,415,661 · 1
P01$2,655,637 · 4
R33$1,961,397 · 1
R21$1,405,950 · 3
Top collaborators
- Daniel R Kuritzkes22 shared
- Roger L Shapiro17 shared
- Xu Yu6 shared
- Jacob D Estes5 shared
- Steven A Yukl5 shared
- Fabio Romerio4 shared
- Linos Vandekerckhove4 shared
- Alonso Heredia1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Xu Yu$21,799,579
- Athe M. Tsibris$17,945,517
- Nina H. Lin$7,153,013
- Daniel S Kohane$17,057,196
- Miguel S Esteves$8,755,816
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralInfectionCellsHiv-1Antiretroviral TherapyCd4 Positive T LymphocytesImmuneViral ReservoirImmune ResponsePharmaceutical PreparationsGenetic TranscriptionMonitorImmunologicsProvirusesMediatingIntegration SiteInterruptionDesignPredispositionAnti-Retroviral AgentsEvolutionPersonsClinical TrialsCohort
Grant awards (76)
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana$1,311,671
U01 · FY2025 · AI
Single-cell Proteogenomic profiling of HIV-1 reservoir cells$1,089,140
R01 · FY2025 · AI · contact PI
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana$889,638
U01 · FY2025 · AI
Immune selection of HIV-1 reservoir cells in human clinical trials$871,246
R01 · FY2025 · AI · contact PI
Selection and Evolution of HIV-1 reservoir cells in blood and tissues$748,304
R01 · FY2025 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 2$462,117
P01 · FY2025 · AI · contact PI
Role of ZNF proteins in the establishment and maintenance of HIV latency$453,750
R21 · FY2025 · AI · contact PI
Pioneering Precision Medicine Approaches for Immune Control of Pediatric HIV-1 Infection$213,939
P01 · FY2025 · HD · contact PI
Mentoring in patient-oriented research to finding a cure for HIV-1 infection$192,097
K24 · FY2025 · AI · contact PI
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana$2,095,803
U01 · FY2024 · AI
Single-cell Proteogenomic profiling of HIV-1 reservoir cells$1,089,140
R01 · FY2024 · AI · contact PI
Molecular profile of proviral reservoirs in HIV-infected drug users$975,058
R33 · FY2024 · DA
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$951,356
U01 · FY2024 · AI
Immune selection of HIV-1 reservoir cells in human clinical trials$895,990
R01 · FY2024 · AI · contact PI
Selection and Evolution of HIV-1 reservoir cells in blood and tissues$751,570
R01 · FY2024 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 2$463,011
P01 · FY2024 · AI · contact PI
Mentoring in patient-oriented research to finding a cure for HIV-1 infection$192,097
K24 · FY2024 · AI · contact PI
Pioneering Precision Medicine Approaches for Immune Control of Pediatric HIV-1 Infection$149,559
P01 · FY2024 · HD · contact PI
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana$1,799,067
U01 · FY2023 · AI
Single-cell Proteogenomic profiling of HIV-1 reservoir cells$1,108,890
R01 · FY2023 · AI · contact PI
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$993,747
U01 · FY2023 · AI
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes$810,339
R01 · FY2023 · DK
Selection and Evolution of HIV-1 reservoir cells in blood and tissues$754,778
R01 · FY2023 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 2$464,957
P01 · FY2023 · AI · contact PI
Mentoring in patient-oriented research to finding a cure for HIV-1 infection$192,097
K24 · FY2023 · AI · contact PI
Pioneering Precision Medicine Approaches for Immune Control of Pediatric HIV-1 Infection$82,537
P01 · FY2023 · HD · contact PI
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$1,395,641
U01 · FY2022 · AI
Molecular profile of proviral reservoirs in HIV-infected drug users$986,339
R33 · FY2022 · DA
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes$810,339
R01 · FY2022 · DK
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 2$513,513
P01 · FY2022 · AI · contact PI
Mentoring in patient-oriented research to finding a cure for HIV-1 infection$192,097
K24 · FY2022 · AI · contact PI
Pioneering Precision Medicine Approaches for Immune Control of Pediatric HIV-1 Infection$82,537
P01 · FY2022 · HD · contact PI
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$1,999,002
U01 · FY2021 · AI
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes$810,339
R01 · FY2021 · DK
Selection and Evolution of HIV-1 reservoir cells in blood and tissues$757,311
R01 · FY2021 · AI · contact PI
Proteomics and phosphoproteomics analysis in HIV-1 infection$517,199
R01 · FY2021 · AI · contact PI
Pioneering Precision Medicine Approaches for Immune Control of Pediatric HIV-1 Infection$223,467
P01 · FY2021 · HD · contact PI
Mentoring in patient-oriented research to finding a cure for HIV-1 infection$190,097
K24 · FY2021 · AI · contact PI
A Pilot Clinical Trial for HIV-1 Eradication$2,373,615
U01 · FY2020 · AI · contact PI
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$1,848,151
U01 · FY2020 · AI
Molecular profile of proviral reservoirs in HIV-infected drug users$1,074,970
R61 · FY2020 · DA
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes$810,339
R01 · FY2020 · DK
Selection and Evolution of HIV-1 reservoir cells in blood and tissues$802,651
R01 · FY2020 · AI · contact PI
Proteomics and phosphoproteomics analysis in HIV-1 infection$517,182
R01 · FY2020 · AI · contact PI
Early Infant Treatment$249,815
U01 · FY2020 · AI
Molecular profile of proviral reservoirs in HIV-infected drug users$168,000
R61 · FY2020 · DA
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$2,158,015
U01 · FY2019 · AI
A Pilot Clinical Trial for HIV-1 Eradication$2,147,412
U01 · FY2019 · AI · contact PI
Molecular profile of proviral reservoirs in HIV-infected drug users$1,076,786
R61 · FY2019 · DA
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes$836,710
R01 · FY2019 · DK
Proteomics and phosphoproteomics analysis in HIV-1 infection$625,344
R01 · FY2019 · AI · contact PI
Quantification of the HIV-1 Reservoir by Immuno-PCR$410,625
R01 · FY2019 · AI
A Pilot Clinical Trial for HIV-1 Eradication$2,150,987
U01 · FY2018 · AI · contact PI
Molecular profile of proviral reservoirs in HIV-infected drug users$1,095,905
R61 · FY2018 · DA
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$1,077,403
U01 · FY2018 · AI
Early Infant Treatment$979,999
U01 · FY2018 · AI
Proteomics and phosphoproteomics analysis in HIV-1 infection$637,308
R01 · FY2018 · AI · contact PI
Quantification of the HIV-1 Reservoir by Immuno-PCR$410,625
R01 · FY2018 · AI
Early Infant Treatment$980,000
U01 · FY2017 · AI
Proteomics and phosphoproteomics analysis in HIV-1 infection$652,471
R01 · FY2017 · AI · contact PI
Quantification of the HIV-1 Reservoir by Immuno-PCR$410,416
R01 · FY2017 · AI
A Pilot Clinical Trial for HIV-1 Eradication$2,139,888
U01 · FY2016 · AI · contact PI
Early Infant Treatment$979,999
U01 · FY2016 · AI
Quantification of the HIV-1 Reservoir by Immuno-PCR$410,000
R01 · FY2016 · AI
A Pilot Clinical Trial for HIV-1 Eradication$1,908,495
U01 · FY2015 · AI · contact PI
Early Infant Treatment$934,543
U01 · FY2015 · AI
Inhibitors of host kinases as molecular targets for immune defense against HIV-1$443,542
R01 · FY2015 · AI · contact PI
Quantification of the HIV-1 Reservoir by Immuno-PCR$218,500
R01 · FY2015 · AI
Early Infant Treatment$979,999
U01 · FY2014 · AI
Inhibitors of host kinases as molecular targets for immune defense against HIV-1$435,000
R01 · FY2014 · AI · contact PI
Limiting HIV-1 persistence by targeting stem cell properties of CD4 T cells$261,000
R21 · FY2014 · AI · contact PI
Inhibitors of host kinases as molecular targets for immune defense against HIV-1$408,900
R01 · FY2013 · AI · contact PI
Limiting HIV-1 persistence by targeting stem cell properties of CD4 T cells$204,450
R21 · FY2013 · AI · contact PI
Inhibitors of host kinases as molecular targets for immune defense against HIV-1$435,416
R01 · FY2012 · AI · contact PI
Innate resistance of CD4 T cells to HIV-1 infection in elite controllers$221,250
R21 · FY2012 · AI · contact PI
Innate resistance of CD4 T cells to HIV-1 infection in elite controllers$265,500
R21 · FY2011 · AI · contact PI